United Therapeutics Acquires Thymmune, Betting 460 Billion Won on Thymus Cell Therapy
The race to develop regenerative cell therapies for an ultra-rare disease that leaves patients born without a thymus—making them highly vulnerable to...
Search results for "United Therapeutics"
Why Urine Darkens During Dehydration: Scientists Uncover the Kidney's Molecular 'Gene Control Switch'
South Korean researchers have uncovered a sophisticated molecular mechanism in the kidneys that regulates water reabsorption, helping the body...
AbTis Wins U.S. Patent Ruling, Safeguarding Core Rights to AbClick Platform
Antibody-drug conjugate developer AbTis announced on August 14 that it has prevailed in an inter partes review before...
Moderna’s Landmark mRNA Cancer Vaccine Phase 3 Success Spotlights Korean Biotech Ties
Positive late-stage clinical results for a personalized messenger RNA cancer vaccine developed by Moderna and Merck are...
Global Asset Managers Expand Holdings in South Korean Pharma and Biotech
Major institutional asset managers are steadily increasing their equity stakes in South Korean pharmaceutical and...
Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal
Samsung Biologics is making a major push into peptide-based medicines—widely used in weight-loss and diabetes...
Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market
The glucagon-like peptide-1 (GLP-1) obesity treatment market, long dominated by subcutaneous injections, is rapidly...
Anchoring the U.S. Supply Chain: GC Green Cross Expands 30-Year Cytiva Partnership to Secure Alyglo Production
GC Green Cross has secured priority access to critical manufacturing consumables to stabilize the production of Alyglo,...
Celltrion Secures South Korean Phase 1 Approval for Tremfya Biosimilar CT-P68
Celltrion announced on July 15 that it has received approval from South Korea’s Ministry of Food and Drug Safety for an...
MediPost Begins Pivotal U.S. Phase 3 Trial for Regenerative Knee Therapy Cartistem
South Korean biotechnology company MediPost has entered full-scale Phase 3 clinical testing in the United States for...